ASH 2021 | The financial burden of CAR T-cell therapy
Surbhi Sidana
• 14 Dec 2021
In recent years, chimeric antigen receptor (CAR) T-cell therapies have been approved for the treatment of various hematological malignancies. However, CAR-T treatment is also associated with a significant cost. Surbhi Sidana, MD, Mayo Clinic, Stanford, CA, talks on the results of a study examining the financial toxicity among patients receiving CAR T-cell therapy. The study found that financial toxicity worsened over the course of treatment, mostly due to travel and caregiver-related expenses. Dr Sidana emphasizes the importance of improving support for patients receiving CAR T-cell therapy. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
